User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Jul 01 2015 22:38 IST RSS 2.0
 
1 to 20 of 2,582    
MPP doubles its generic partners, adds more domestic drug firms 1.7.2015 TOI: Cities
The Medicines Patent Pool (MPP) announced the expansion of its network of generic manufacturers to 14 companies now working on over 50 projects to develop MPP-licensed antiretrovirals ...
Also found in: [+]
Glenmark gets US regulator nod for cholesterol drug 30.6.2015 Sify Finance
India's leading new molecules maker Glenmark Pharmaceuticals has received approval from the US Food and Drug Administration (USFDA) for its cholesterol-lowering drug Ezetimibe.
Also found in: [+]
Sensex edges higher, looks set to cross 28,000 mark again 24.6.2015 Sify Finance
Also found in: [+]
Focus on data privacy laws to boost medical outsourcing 23.6.2015 ET: Healthcare
The government should introduce proper regulations for intellectual property and patents besides focusing on implementing data privacy laws, a study said.
Also found in: [+]
Single-window clearance for pharma sector on anvil: Union Minister Ananth Kumar 23.6.2015 DNA: Mumbai
To enable a single-window clearance system in pharmaceuticals sector, the government will set up a high-level committee next week to work out the modalities for the same. The committee will be headed by Pharmaceuticals Secretary V K Subburaj and the move follows a recommendation by the task force on enabling the private sector to lead the growth of the pharmaceuticals sector. "It (committee) will suggest a mechanism for single-window clearance for the pharmaceuticals industry," Chemicals and Fertiliser Minister Ananth Kumar told PTI. Stressing on the importance of having a single authority for clearance in the sector, he said key decision-making powers on various important aspects such "patents, licencing and pricing are with different departments". While the issue of patents is dealt by Department of Industrial Policy & Promotion, drug licence is given by Drug Controller General of India under Health Ministry and pricing is controlled by NPPA, under Pharmaceuticals Department. "This coordination ...
Also found in: [+]
Single-window clearance for pharma sector on anvil: Ananth Kumar 22.6.2015 ET: Policy
To enable a single-window clearance system in pharma sector, govt will set up a high-level committee next week to work out the modalities for the same.
Also found in: [+]
Chinese firms pour money into US R&D in shift to innovation 21.6.2015 TOI: Intl Business
Surging investment by Chinese companies in U.S. research labs is yielding a fast-growing trove of patents, part of a push to mine America for ideas to help China shift from being the world's factory floor to a driver of innovation.
Also found in: [+]
US court rejects Teva’s Copaxone patent plea 20.6.2015 TOI: India Business
In a major booster for city-based Natco Pharma, the US Court of Appeals for the Federal Circuit has again struck down Israeli pharma giant Teva Pharmaceutical Industries Ltd’s Copaxone patent, paving the way for Natco Pharma to manufacture the copycat version of the drug subject to the United States Food And Drug Administration (USFDA) nod.
Also found in: [+]
India to resist Japan and South Korea's push for patent legislation at RCEP 12.6.2015 ET: Policy
Japan is pushing for patents to be granted for incremental innovations, even if they don’t show any improved efficacy over an existing invention.
Also found in: [+]
Dr AK Dwivedi nominated scientific advisory committee member 5.6.2015 TOI: Cities
The ministry of AYUSH has nominated Gujarati Homeopathic Medical College professor Dr AK Dwivedi as member of scientific advisory committee of Central Homeopathic Research ...
Also found in: [+]
US co Abraxis denied patent on cancer drug 3.6.2015 TOI: India Business
The Indian Patent Office has refused a patent on US firm Abraxis BioSciences’ anti-cancer drug Abraxane, paving the way for generic companies to launch affordable versions in the domestic market. The application on the Abraxane formulation was refused since it lacks inventive step, and violates Section 3 (d) of the Indian Patent Act -- a provision under which Swiss company Novartis lost the patent on its blockbuster cancer drug, Glivec in 2013.
Also found in: [+]
Lupin plans cancer drug unit in Mihan 25.5.2015 Nagpur News, Nagpur City News | Cities News - Times of India
Lupin plans cancer drug unit in Mihan
Also found in: [+]
Suven Life Sciences gets patents for neurodegenerative drug 22.5.2015 TOI: India Business
Biopharmaceutical firm Suven Life Sciences on Friday said it has been granted one patent each by Mexico and Singapore for a drug used in the treatment of neurodegenerative diseases.
Also found in: [+]
India eyes 15% jump in medicine exports this fiscal 21.5.2015 ET: Healthcare
Indian drug makers are hopeful of achieving double digit growth in exports this fiscal after being confined to single digit growth for two years.
Also found in: [+]
UPDATE 1-Indian court bars Glenmark from selling Merck drug copies 15.5.2015 Sify Finance
(Adds details from court order)
Also found in: [+]
Supreme Court bars Glenmark from selling Merck drug copies 15.5.2015 Sify Finance
MUMBAI (Reuters) - The Supreme Court of India has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet,
Also found in: [+]
Suven Life Sciences gets patents for neurological drug 13.5.2015 TOI: India Business
Pharmaceutical firm Suven Life Sciences on Wednesday said it has been granted one patent each by Europe and Hong Kong for a drug used in the treatment of neurodegenerative diseases.
Also found in: [+]
Awareness about AYUSH 8.5.2015 Govt of india: PIB
National Sample Survey Office (NSSO) in their 68th round (July 2011-June 2012) on socio economic household surveys has collected information on awareness and acceptability of AYUSH.
Also found in: [+]
US pharma sector welcomes India's intellectual property policy 6.5.2015 ET: Pharma
The US pharma sector has welcomed India's recent moves on intellectual property, including bringing out a draft policy and sustained engagement.
Also found in: [+]
India fully aligned with international IPR, will safeguard its own interests, says Nirmala Sitharaman 4.5.2015 ET: Policy
Different arms of the government are not speaking the same language on IPR, which is leading to confusion on where India stands on these issues.
Also found in: [+]
1 to 20 of 2,582